Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas

Leukemia and Lymphoma

Volumn 35, Issue 1-2, 1999, Pages 129-138

  Rummel, Mathias J ^a   Chow, Kai U ^a   Jäger, Elke ^b   Leimer, Lothar ^c   Hossfeld, Dieter K ^d   Bergmann, Lothar ^e   Peters, Hans D ^f   Hansmann, Martin L ^a   Meyer, Annette ^a   Hoelzer, Dieter ^a   Mitrou, Paris S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

2 CdA; Cladribine; Low grade non Hodgkin's lymphoma; Treatment

Indexed keywords

CLADRIBINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INFUSION; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032829272     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909145712     Document Type: Article

References (35)

1. The Non-Hodgkin's Lymphoma pathologic classification project National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage (1982). Cancer, 49, 2112-2135.
2. Lennert, K., Feller, A. C. Histopathologie der Non-Hodgkin Lymphome (nach der aktualisierten Kiel-Klassifikation) (1990). Berlin-Heidelberg-New York, Springer.
3. Horning, S. J., Rosenberg, S. A. (1984). The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med, 311, 1471-1475.
4. Beutler, E. (1992). Cladribine (2-Chlorodeoxyadenosine). Lancet, 340, 952-956.
5. Carson, D. A., Wasson, D. B., Taetle, R., et al. (1983). Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood, 62, 737-743.
6. Seto, S., Carrera, C. J., Kubota, M., et al. (1985). Mechanism of deoxyadenosine and 2-chlorode-oxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest, 75, 377-383.
7. Kay, A. C. Saven, A., Carrera, C. J., et al. (1992) 2-Chlorodeoxyadenosine in low grade lymphoma. J Clin Oncol, 10, 371-377.
8. Hickish, T., Serafinowski, P., Cunningham, D., et al. (1993) 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer, 67, 139-143.
9. Hoffman, M., Tallman, M. S., Hakimian, D., et al. (1994) 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodkin's lymphoma. J Clin Oncol, 12, 788-792.
10. Dimopoulos, M. A., Weber, D., Delasalle, K. B., et al. (1995) Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol, 6, 49-52.
11. Liliemark, J., Porwit, A., Juliusson, G. (1997) Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leak Lymph, 25, 313-318.
12. Robak, T, G6ra-Tybor, J., Krykowski, E., et al. (1997) Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. Leak Lymph. 26, 99-105.
13. Rondelli, D., Lauria, F., Zinzani, P. L., et al. (1997) 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haemalol, 58, 46-50.
14. Harris, N. J., Jaffe, E. S., Stein, H., et al. (1994) A revised European-American classification of lymphoid neoplasms; A proposal from the International Lymphoma Study Group. Blood, 84 1361-1392.
15. Shipp, M. A., Harrington, D. P. A. JR, Armitage, J. O., et al. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 329, 987-994.
16. Dimopoulos, M. A., Kantarjian. H., Weber, D., et al. (1994) Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 12, 2694-2698.
17. Saven, A., Emanuele, S., Kosty, M., et al. (1995) 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood, 86, 1710-1716.
18. Betticher, D. C., Zucca, E., von Rohr, A., et al. (1996) 2-chlorodeoxyadenosine (2-CdA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol, 7, 793-799.
19. Canfield, V. A., Vose, J., Guiney, P., et al. (1997) 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas. Leak Lymph, 24, 335-339.
20. Liliemark, J., and Juliusson, G. (1995) Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Canc Rex, 1, 385-390.
21. Liliemark, J., Martinsson, U., Cavallin-Stahl, E., et al. (1998) Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk Lymph, 30, 573-581.
22. Armitage, J. O., et al. (1997) The non-Hodgkin's lymphoma classification project: A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood, 89, 3909-3918.
23. Brittinger, G., Bartels, H., Common, H., et al. (1986) Klinische und prognostische Relevanz der Kiel-Klassifikation der non-Hodgkin Lymphome. Onkologie, 9, 118-125.
24. Zucca, E., Fontana, S., Roggero, E., et al. (1994) Treatment and prognosis of centrocytic (mantle cell) lymphoma: A retrospective analysis of twenty-six patients treated in one institution. Leuk Lymph, 13, 105-110.
25. Zucca, E., Roggero, E., Pinotti, G., et al. (1995) Patterns of survival in mantle cell lymphoma. Ann Oncol, 6, 257-262.
26. Estey, E. H., Kurzrock, R., Kantarjian, H. M., et al. (1992) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood. 79, 882-887.
27. Unterhalt, M., Hermann, R., Tiemann, M., et al. (1996) Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. Leukemia, 10, 836-843.
28. Betticher, D. C., Fey, M. F., von Rohr, A., et al. (1994) High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol, 5, 57-64.
29. Saven, A., Burian, C., Koziol, J., et al. (1997) Lomg-term follow up of patients with hairy cell leukemia (HCL) following cladribine treatment. Blood, 90 (Suppl 1 ), 578a (Abstr 2573).
30. Kurzrock, R., Strom, S. S., Estey, E., et al. (1997) Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol, 15, 1803-1810.
31. Karlsson, K., Strömberg, M., Johnson, S., et al. (1996) Three-day three-weekly oral cladribine (2-CdA) for chronic lymphocytic leukemia. A preliminary report from a European phase 11 multicenter study. Ann Oncol, 7 (Suppl 3), 68 (Abstr 239).
32. Betticher, D. C., von Rohr, A., Ratschiller, D., et al. (1998) Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. J Clin Oncol, 16, 850-858.
33. Betticher, D. C., Ratschiller, D., Hsu Schmitz, S. F., et al. (1998) Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann Oncol, 9, 721-726.
34. Saven, A., Lee, T., Kosty, M. and Piro, L. (1996) Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol. 14, 2139-2144.
35. Mitrou, P. S., Chow, K. U., Rummel, M., et al. (1998) Synergistic effects of 2-CdA and other cytotoxic drugs on apoptosis of normal and malignant lymphocytes. J Cancer Res Clin Oncol. 124 (Suppl), R59 (Abstr 14.28.02).